A study of 40 adults with constipation shows that the patients given
Lactobacillus reuteri Protectis were significantly less constipated after four
weeks compared to the patients given placebo.
In the double blind, placebo-controlled study 40 adults, diagnosed with
functional constipation, were supplemented with either two chewable tablets per
day of Lactobacillus reuteri Protectis or corresponding placebo. The
intervention period was four weeks and constipation was measured as number of
bowel movements per week. Bowel movements were recorded for each patient at the
start of the study and after four weeks (end of study).
At the end of the study the group given Lactobacillus reuteri Protectis had
significantly more bowel movements per week than the group given placebo. The
results are the first with Lactobacillus reuteri Protectis in adult patients
with functional constipation and confirm earlier positive data in children.
The results were published in J Gastrointestin Liver
Dis (http://www.jgld.ro/2014/4/9.html) on 9 December 2014. Study details are
found through the attached
link (http://www.biogaia.com/sites/biogaia.com/files/Study_details_Ojetti_Decemb
e
r_2014.pdf).
“Constipation is a common problem world wide and many of the current treatment
options have side effects. Lactobacillus reuteri Protectis has already been
shown to be an effective alternative in children and it is satisfying that the
new results confirm that this also applies to adults with constipation”, says
Peter Rothschild, President, BioGaia.
Latest press releases from BioGaia
2014-12-01 BioGaia invests in promising research company
2014-10-24 Infants with colic cry less with BioGaia’s drops
2014-10-22 BioGaia AB Interim management report 1 January – 30 September 2014
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 11 December 2014,
09:30 am CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
